Replies to post #166854 on Avid Bioservices Inc (CDMO)

[stoneroad]

Microbeman, I am interested in why you are a large and long term shareholder when you consistently find issue with Peregrine's data/results. You appear to be extremely knowledgeable. Can you explain the dichotomy? Thank you.

[sulaco]

Microbe man, you are incorrect - First, the anti-CTLA-4


presentation at SITC showed that Bavi and anti-CTLA-4 resulted in the lowest murine tumor volume of ALL combinations. Survival was NOT a metric. The Hemotoxylin and Eosin slides also definitely showed the most tumor destruction with the Bavi and anti-CTLA-4 combination, not anti-CTLA-4 alone.

check it yourself


You state to Stoneroad:

That will probably be correct since the anti-PS + anti CTL4A combo actually gave lower final survival numbers that CTLA4 alone. I may be missing something, but I don't find anything to date about these immunotherapy combinations that gets me very excited.

Wrong.

No study with either anti-PD-1 or anti-CTLA-4 combined with Bavi ever mentioned survival AT ALL. The SITC study measured tumor volume, and the Keystone study measured TUMOR SUPPRESSION not survival.

To review the recent Keystone results:

Results from these preclinical studies found that animals administered a combination of a PS-targeting antibody and an anti-CTLA-4 or an anti-PD-1 antibody exhibited greater tumor growth suppression and longer survival than anti-CTLA-4 and anti-PD1 antibodies alone.

In other words, yes, you ARE missing something. I have no idea why you quote "survival" in these studies, which was never mentioned as a metric in any of these studies.

Your post contains so many errors, it's hard to take you seriously.


Please think before you post when trying to contribute to the Board.


Best,

Joe